Congestive Heart Failure
Updated: 01/25/2006
References
Adlam D , Silcocks P , et al. Using BNP to develop a risk score for heart failure in primary care. Eur Heart J . 2005;26:1086-1093.
Ahmed A. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice. J Am Geriatr Soc. 2003;51:123-126.
American Heart Association. Heart Disease and Stroke Statistics—2004 Update . Dallas , Tex : American Heart Association; 2004.
Anker SD , Chua TP , et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526-534.
Awata N, et al. The effects of coenzyme Q10 on ischemic heart disease evaluated by dynamic exercise test. In: Yamamura Y, Folkers K, et al, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 2. Amsterdam , Netherlands : Elsevier-North Holland Biomedical; 1980:247-254.
Benedict CR, Johnstone DE , et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol. 1994;23:1410-1420.
Berger MM , Mustafa I . Metabolic and nutritional support in acute cardiac failure. Curr Opin Clin Nutr Metab Care. 2003;6:195-201.
Berman M, Erman A, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol. 2004;27:295-299.
Braunwald E. Heart failure. In: Braunwald E, Fauci AS, et al, eds. Harrison's Principles of Internal Medicine. 15th ed. New York , NY : McGraw Hill Professional Publishing; 2001:1318-1328.
Cohen N, Alon I, et al. Metabolic and clinical effects of oral magnesium supplementation in furosemide-treated patients with severe congestive heart failure. Clin Cardiol. 2000;23:433-436.
Colonna P, Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. Am Heart J. 2000;139(pt 3):S124-S130.
Crane FL , Navas P. The diversity of coenzyme Q function. Mol Aspects Med. 1997;18(suppl):S1-S6.
Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int. 1987;31:1402-1415.
Dzau VJ, Colucci WS, et al. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63:645-651.
Dzugan SA, Arnold Smith R. Hypercholesterolemia treatment: a new hypothesis or just an accident? Med Hypotheses. 2002;59:751-756.
Eichholzer M, Stahelin HB, et al. Inverse correlation between essential antioxidants in plasma and subsequent risk to develop cancer, ischemic heart disease and stroke respectively: 12-year follow-up of the Prospective Basel Study. EXS. 1992;62:398-410.
Fedak PW, Verma S, et al. Cardiac remodeling and failure: from molecules to man (part I). Cardiovasc Pathol. 2005;14:1-11.
Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Prev Cardiol. 2000;3:24-32.
Frei B, Kim MC, et al. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci USA . 1990;87:4879-4883.
Goa KL, Brogden RN. L-carnitine: a preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs. 1987;34:1-24.
Hunt SA, Baker DW, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant. 2002;21:189-203.
Jeejeebhoy F, Keith M, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. 2002;143:1092-1100.
Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007-2018.
Judy WV, Folkers K, et al. Improved long-term survival in coenzyme Q10 treated chronic heart failure patients compared to conventionally treated patients. In: Folkers K, Littarru GP, et al, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 4. Amsterdam , Netherlands : Elsevier Science;1991:291-298.
Kontoleon PE, Anastasiou-Nana MI, et al. Hormonal profile in patients with congestive heart failure. Int J Cardiol. 2003;87:179-183.
Kostis JB, Shelton BJ, et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J. 1994;128:358-364.
Leuchtgens H. Crataegus Special Extract WS 1442 in NYHA II heart failure: a placebo controlled randomized double-blind study. Fortschr Med. 1993;111:352-354.
Mancini M, Rengo F, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. A rzneimittelforschung. 1992;42:1101-1104.
Maxwell SR. Can anti-oxidants prevent ischaemic heart disease? J Clin Pharm Ther. 1993;18:85-95.
McCullough PA, Philbin EF, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study . J Am Coll Cardiol. 2002;39:60-69 .
Moriyama Y, Yasue H, et al. The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab. 2000;85:1834-1840.
Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure; rationale, design and end-points of “Q-symbio”—a multinational trial. Biofactors. 2003;18:79-89.
Nakamura Y, Takahashi M, et al. Protection of ischaemic myocardium with coenzyme Q10. Cardiovasc Res. 1982;16:132-137.
Nayler WG. The use of coenzyme Q10 to protect ischaemic heart muscle. In: Yamamura Y, Folkers K, et al, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 2. Amsterdam , Netherlands : Elsevier-North Holland Biomedical; 1980:409-425.
Ondarroa M, Quinn PJ. Proton magnetic resonance spectroscopic studies of the interaction of ubiquinone-10 with phospholipid model membranes. Eur J Biochem. 1986;155:353-361.
Patrick L. Mercury toxicity and antioxidants, part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. Alter Med Rev. 2002;7:456-471.
Pucciarelli G, Mastursi M, et al. The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure . Clin Ter. 1992;141:379-384.
Pugh PJ, Jones RD , et al. Testosterone treatment for men with chronic heart failure. Heart. 2004;90:446-447.
Schaffer SW, Lombardini JB, et al. Interaction between the actions of taurine and angiotensin II. Amino Acids. 2000;18:305-318.
Schmidt U, et al. Efficacy of the hawthorn (Crataegus) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. Phytomedicine. 1994;1:17-24.
Schwinger RH, Pietsch M, et al. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol. 2000;35:700-707.
Steg PG , Joubin L , et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest. 2005;128:21-29.
Taggart DP, Jenkins M, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Ann Thorac Surg. 1996;61:829-833.
Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J. 2002;143:910-915.
Tauchert M, Gildor A, et al. High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure . Herz. 1999;24:465-474.
Weant KA , Smith KM . The role of coenzyme Q10 in heart failure. Ann Pharmacother. 2005;39:1522-1526.
Weikl A, Assmus KD, et al. Crataegus Special Extract WS 1442: assessment of objective effectiveness in patients with heart failure (NYHA II). Fortschr Med. 1996;114:291-296.
Weisberg AD, Albornoz F, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotension II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol. 2005;25:365-371.
Witte KK , Clark AL . Fish oils—adjuvant therapy in chronic heart failure? Eur J Cardiovasc Prev Rehabil. 2004;11:267-274.
Witte KK , Nikitin NP , et al. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J. 2005
Zile MR , Brutsaert DL . New concepts in diastolic dysfunction and diastolic heart failure, part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:1387-1393.